Tango Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Tango Therapeutics, Inc. | ||
| Date: March 5, 2026 | By: | /s/ Malte Peters |
|---|---|---|
| Malte Peters, MD | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY
Each person whose individual signature appears below hereby authorizes and appoints Malte Peters, Daniella Beckman and Julie Fogarty, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Malte Peters | President and Chief Executive Officer, Director | March 5, 2026 |
| Malte Peters, MD | (Principal Executive Officer) | |
| /s/ Daniella Beckman | Chief Financial Officer | March 5, 2026 |
| Daniella Beckman | (Principal Financial Officer) | |
| /s/ Barbara Weber, MD | Executive Chairman of the Board of Directors | March 5, 2026 |
| Barbara Weber, MD | ||
| /s/ Alexis Borisy | Director | March 5, 2026 |
| Alexis Borisy | ||
| /s/ Lesley Ann Calhoun | Director | March 5, 2026 |
| Lesley Ann Calhoun | ||
| /s/ Kanishka Pothula | Director | March 5, 2026 |
| Kanishka Pothula | ||
| /s/ John Ketchum | Director | March 5, 2026 |
| John Ketchum | ||
| /s/ Sung Lee | Director | March 5, 2026 |
| Sung Lee | ||
| /s/ Mace Rothenberg | Director | March 5, 2026 |
| Mace Rothenberg, MD | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss | F-5 |
| Consolidated Statements of Stockholders’ Equity | F-6 |
| Consolidated Statements of Cash Flows | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.